Wave waves goodbye to its first generation
The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
Proqr hopes to usherin a new ophthalmic therapy
The group’s antisense project is the only game in town for Usher syndrome, but its latest trial is not a slam-dunk.
Biotech’s important clinical data readouts
The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Big pharma’s key catalysts in the second quarter
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
Better late than never for Boehringer in Covid-19
Boehringer says its inhaled antibody could reach the patients IV antibodies cannot, but will be “very happy” if it isn’t needed.
Cognito’s Alzheimer’s brainwave
Gamma frequency neuromodulation is the key to treating dementia, according to the MIT spinout.
Frequency refuses to hear the death knell
The company placed part of the blame for its mid-stage hearing loss failure on subjects exaggerating their level of hearing loss.
The Huntington’s pipeline takes a blow
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
Wave gets another shot at Huntington’s
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
